Matt serves as a Senior Advisor to Out Leadership’s Quorum initiative, and is an advisor to life sciences companies, executive teams and investors. From 2009 through 2013, he was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, a NASDAQ-listed biotechnology company, culminating in the company’s sale to Amgen. He previously served as Senior Vice President and Chief Financial Officer of Jazz Pharmaceuticals, a NASDAQ-listed biopharmaceutical company; Chief Financial Officer of Perlegen Sciences, a privately-held genetics company; and Senior Vice President and Chief Financial Officer of ALZA Corporation, an American Stock Exchange-listed pharmaceutical company. Prior to joining ALZA, Matt was a member of the healthcare strategy consulting practice at Andersen Consulting (now Accenture). Matt serves on the boards of directors, and on audit, compensation and nominating committees, for several companies, including Atara Biotherapeutics, Dermira, MacroGenics, and Ultragenyx Pharmaceutical. He holds an undergraduate degree from the University of Minnesota and an M.B.A. from the Stanford University Graduate School of Business.